186 related articles for article (PubMed ID: 36239200)
1. Addition of interleukin-6 receptor blockade to carfilzomib-based desensitization in a highly sensitized nonhuman primate model.
Anwar IJ; Ezekian B; DeLaura I; Manook M; Schroder P; Yoon J; Curfman V; Branum E; Messina J; Harnois M; Permar SR; Farris AB; Kwun J; Knechtle SJ
Am J Transplant; 2022 Dec; 22 Suppl 4(Suppl 4):1-11. PubMed ID: 36239200
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.
Ezekian B; Schroder PM; Mulvihill MS; Barbas A; Collins B; Freischlag K; Yoon J; Yi JS; Smith F; Olaso D; Saccoccio FM; Permar S; Farris AB; Kwun J; Knechtle SJ
J Am Soc Nephrol; 2019 Dec; 30(12):2399-2411. PubMed ID: 31658991
[TBL] [Abstract][Full Text] [Related]
3. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.
Schroder PM; Schmitz R; Fitch ZW; Ezekian B; Yoon J; Choi AY; Manook M; Barbas A; Leopardi F; Song M; Farris AB; Collins B; Kwun J; Knechtle SJ
Kidney Int; 2021 Jan; 99(1):161-172. PubMed ID: 32898569
[TBL] [Abstract][Full Text] [Related]
4. [Improving access to kidney transplantation for highly sensitized patients: What place for IL-6 pathway blockade in desensitization protocols?].
Weinhard J; Noble J; Jouve T; Malvezzi P; Rostaing L
Nephrol Ther; 2022 Dec; 18(7):577-583. PubMed ID: 36328901
[TBL] [Abstract][Full Text] [Related]
5. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
6. Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates.
Schmitz R; Fitch ZW; Manook M; Schroder PM; Choi AY; Olaso D; Yoon J; Bae Y; Shaw BI; Song M; Kuchibhatla M; Farris AB; Kirk A; Kwun J; Knechtle SJ
Kidney360; 2022 Dec; 3(12):2116-2130. PubMed ID: 36591367
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients.
Green H; Nesher E; Aizner S; Israeli M; Klein T; Zakai H; Rahamimov R; Rozen-Zvi B; Mor E
Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818
[TBL] [Abstract][Full Text] [Related]
8. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.
Choi AY; Manook M; Olaso D; Ezekian B; Park J; Freischlag K; Jackson A; Knechtle S; Kwun J
Front Immunol; 2021; 12():694763. PubMed ID: 34177960
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
[TBL] [Abstract][Full Text] [Related]
10. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
Kimball PM; McDougan FA; King A
Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
[TBL] [Abstract][Full Text] [Related]
11. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
12. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.
Vo AA; Huang E; Ammerman N; Toyoda M; Ge S; Haas M; Zhang X; Peng A; Najjar R; Williamson S; Myers C; Sethi S; Lim K; Choi J; Gillespie M; Tang J; Jordan SC
Am J Transplant; 2022 Apr; 22(4):1133-1144. PubMed ID: 34910841
[TBL] [Abstract][Full Text] [Related]
13. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
14. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation.
Wang HD; Fidder SAJ; Miller DT; Furtmüller GJ; Ahmadi AR; Nägele F; Lopez J; Quan A; Budihardjo J; Lough DM; Akpinarli B; Etra JW; Vasilic D; Raimondi G; Lee WPA; Montgomery RA; Sun Z; Brandacher G
Transplantation; 2018 Apr; 102(4):593-600. PubMed ID: 29298238
[TBL] [Abstract][Full Text] [Related]
15. Renal transplantation across the donor-specific antibody barrier: Graft outcome and cancer risk after desensitization therapy.
Yang CY; Lee CY; Yeh CC; Tsai MK
J Formos Med Assoc; 2016 Jun; 115(6):426-33. PubMed ID: 26725772
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients.
Razia D; Hu C; Cherrier L; Nasar A; Walia R; Tokman S
Transpl Immunol; 2022 Dec; 75():101703. PubMed ID: 36049718
[TBL] [Abstract][Full Text] [Related]
17. APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice.
Wilson NA; Bath NM; Verhoven BM; Ding X; Boldt BA; Sukhwal A; Zhong W; Panzer SE; Redfield RR
Transplantation; 2019 Jul; 103(7):1372-1384. PubMed ID: 30830041
[TBL] [Abstract][Full Text] [Related]
18. Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model.
Bath NM; Ding X; Wilson NA; Verhoven BM; Boldt BA; Sukhwal A; Reese SR; Panzer SE; Djamali A; Redfield RR
PLoS One; 2019; 14(2):e0211865. PubMed ID: 30735519
[TBL] [Abstract][Full Text] [Related]
19. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.
Jordan SC; Reinsmoen N; Lai CH; Cao K; Kahwaji J; Peng A; Villicana R; Vo A
Transplant Proc; 2012 Jan; 44(1):60-1. PubMed ID: 22310579
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
